Susquehanna Fundamental Investments LLC Acquires New Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Susquehanna Fundamental Investments LLC purchased a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 59,436 shares of the company's stock, valued at approximately $2,391,000. Susquehanna Fundamental Investments LLC owned 0.09% of Kymera Therapeutics as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in KYMR. Franklin Resources Inc. lifted its holdings in Kymera Therapeutics by 35.1% during the third quarter. Franklin Resources Inc. now owns 29,440 shares of the company's stock valued at $1,356,000 after purchasing an additional 7,647 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Kymera Therapeutics by 212.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company's stock worth $6,649,000 after buying an additional 95,547 shares during the period. Harbor Capital Advisors Inc. grew its stake in Kymera Therapeutics by 1.7% in the 4th quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company's stock valued at $1,649,000 after buying an additional 684 shares in the last quarter. Blue Trust Inc. raised its holdings in Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after acquiring an additional 270 shares during the period. Finally, KBC Group NV raised its holdings in Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after acquiring an additional 752 shares during the period.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on KYMR shares. Stephens reiterated an "overweight" rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. HC Wainwright upped their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Finally, Citigroup began coverage on shares of Kymera Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $52.00 price target for the company. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $56.36.

Kymera Therapeutics Stock Performance

KYMR stock traded down $1.33 during trading on Monday, hitting $33.96. 119,658 shares of the company traded hands, compared to its average volume of 655,949. Kymera Therapeutics, Inc. has a 1 year low of $19.44 and a 1 year high of $53.27. The company has a 50-day moving average of $29.68 and a 200-day moving average of $38.12. The firm has a market capitalization of $2.21 billion, a PE ratio of -14.53 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). The business had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling

In related news, CFO Bruce N. Jacobs sold 7,035 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares of the company's stock, valued at $6,147,428.70. This represents a 3.37 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the transaction, the chief operating officer now directly owns 67,800 shares of the company's stock, valued at $2,064,510. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,659 shares of company stock valued at $324,567 over the last three months. Corporate insiders own 15.82% of the company's stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.